Rating Change
CICC analysts initiated coverage on Merck & Co., Inc. (NYSE:MRK) with a Outperform rating on June 24, 2026.
new coverageNYSE:MRK
CICC Initiates Coverage on Merck & Co., Inc. (MRK) with Outperform
Rating Change CICC analysts initiated coverage on Merck & Co., Inc. (NYSE:MRK) with a Outperform rating on June 24, 2026. Market Context Merck & Co., Inc.
Market Context
Merck & Co., Inc. operates in the Healthcare sector. The stock currently trades at $120.65 with a market capitalization of $248.8B. The stock has gained 39.8% over the past 52 weeks.
Analyst coverage from CICC provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Merck & Co., Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Merck & Co., Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 24, 2026 | CICC | Outperform | N/A |
| May 06, 2026 | Citigroup | Neutral | N/A |
| May 01, 2026 | Wells Fargo | Overweight | N/A |
| Apr 13, 2026 | UBS | Buy | N/A |
| Apr 06, 2026 | JP Morgan | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View MRK Stock Page
Frequently Asked Questions
What does a Outperform rating mean for MRK?
A Outperform rating from CICC reflects the analyst's outlook on Merck & Co., Inc. (NYSE:MRK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRK forecast page.
